What is the future of inhaled antibiotics for bronchiectasis?

Emma D. Johnson; James D. Chalmers

doi:10.1080/17476348.2024.2423825

What is the future of inhaled antibiotics for bronchiectasis?

Emma D. Johnson, James D. Chalmers (Lead / Corresponding author)

Respiratory Medicine and Gastroenterology

Research output: Contribution to journal › Editorial › peer-review

Original language	English
Pages (from-to)	907-912
Number of pages	6
Journal	Expert Review of Respiratory Medicine
Volume	18
Issue number	12
DOIs	https://doi.org/10.1080/17476348.2024.2423825
Publication status	Published - 3 Nov 2024

Keywords

Bronchiectasis
Clinical trials
Endotypes
Exacerbations
Inhaled antibiotics

ASJC Scopus subject areas

Immunology and Allergy
Pulmonary and Respiratory Medicine
Public Health, Environmental and Occupational Health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/17476348.2024.2423825

Cite this

@article{9aec0738ee454a47b28c6710836692e1,

title = "What is the future of inhaled antibiotics for bronchiectasis?",

keywords = "Bronchiectasis, Clinical trials, Endotypes, Exacerbations, Inhaled antibiotics",

author = "Johnson, {Emma D.} and Chalmers, {James D.}",

note = "{\textcopyright} 2024 Informa UK Limited, trading as Taylor & Francis Group",

year = "2024",

month = nov,

day = "3",

doi = "10.1080/17476348.2024.2423825",

language = "English",

volume = "18",

pages = "907--912",

journal = "Expert Review of Respiratory Medicine",

issn = "1747-6348",